On September 16, 2026, Needham upgraded Rocket Pharmaceuticals (NASDAQGM:RCKT) from a “Hold” to a “Buy” rating, signaling a potential positive outlook for the company. The stock closed at $3.49, a slight increase from $3.41 on September 15, 2026. Over the past week, Rocket Pharmaceuticals saw a price change of -3.86%, while the one-month outlook indicates a change of +0.58%.
Concurrent with Needham’s action, Wedbush reiterated its “Outperform” rating, while Chardan Capital maintained its “Buy” rating on September 15, 2026. The overall analyst consensus includes 4 strong buy, 7 buy, 7 hold, and 2 sell recommendations, reflecting 55% positive sentiment based on 20 total recommendations.
Following an earnings report on August 10, 2026, Rocket Pharmaceuticals reported an actual EPS of -0.48 against an estimate of 0.2467, resulting in a surprise of -294.57%. The actual revenue was reported at $0.00 against expectations of $20.4 million.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
